EUVIMEDEUVIMED entdecken
Crossref

L26/P-495 Pregnancy outcomes following add-on interventions in women aged <40 years with refractory recurrent implantation failure after six failed embryo transfers managed under the OPTIMUM protocol

A. Moriyama, K. Kuroda, R. Tsutsumi, S. Ohgi, R. Hobo, R. Nakagawa, M. Nakata, H. Motoyama, Y. Kuribayashi, R. Sugiyama

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Moriyama und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question What are the pregnancy outcomes in women under 40 with recurrent implantation failure (RIF) after six failed embryo transfers (ETs) managed under the OPTIMUM protocol? Summary answer Approximately two-thirds of women achieved an ongoing pregnancy by the 7th–10th ET; however, additional add-on interventions showed no significant benefit. What is known already In Japan, public insurance coverage allows women aged <40 years to undergo up to six ET cycles. Although insurance coverage has reduced the financial burden of assisted reproductive technology (ART), a portion of the add-on tests and treatments, including preimplantation genetic testing for aneuploidy (PGT-A), are generally not covered, and their clinical effectiveness remains controversial, particularly in young women with RIF. Study design, size, duration This retrospective cohort study included 3,508 women aged <40 years who underwent ART under the national insurance system between April 2022 and September 2025. Among them, 67 women (1.9%) failed to achieve an ongoing pregnancy after six ETs. After excluding 11 women including those who declined further ET or the OPTIMUM (OPtimization of Thyroid function, Thrombophilia, IMmunity, and Uterine Milieu) protocol, 56 women undergoing a seventh or later ET were analyzed. Participants/materials, setting, methods Women with ≥3 failed ETs or ≥ 2 miscarriages were managed using the OPTIMUM protocol. RIF testing included hysteroscopy, endometrial CD138 immunostaining, and assessment of thyroid, immunological, and thrombophilic factors. Targeted treatments included antibiotics for chronic endometritis, vitamin D or tacrolimus for elevated Th1/Th2 ratios, levothyroxine for hypothyroidism, and low-dose aspirin for thrombophilia. Additional add-ons (PGT-A, platelet-rich plasma [PRP], endometrial microbiome, and endometrial receptivity testing) were provided at the discretion of the physician and patient. Main results and the role of chance Overall, 66.1% (37/56) of the women achieved ongoing pregnancy by the 7th–10th ET. Women in the success group were significantly younger (34.3 ± 3.1 vs. 36.4 ± 3.5 years, p = 0.004) and had higher AMH levels (3.6 ± 2.5 vs. 2.0 ± 1.5 ng/mL, p = 0.02) than did those in the failure group (implantation failure or miscarriage). No significant differences in the prevalence of recurrent pregnancy loss, number of ETs prior to the OPTIMUM protocol, or causes of infertility were observed between the groups. Likewise, no significant differences in the use of additional add-ons were observed between the failure and success groups, including PGT-A (36.8% vs. 45.9%, p = 0.58), intrauterine PRP infusion (26.3% vs. 8.1%, p = 0.11), probiotic treatment based on endometrial microbiome testing (36.8% vs. 24.3%, p = 0.36), or personalized ET based on endometrial receptivity testing (73.7% vs. 70.3%, p = 1.00). Notably, 68.4% (13/19) of women in the failure group discontinued treatment after the 7th or 8th ET. Limitations, reasons for caution The study was limited by its retrospective design, small sample size, and single-center setting. Wider implications of the findings Among women aged <40 years with refractory RIF managed under the OPTIMUM protocol, pregnancy outcomes appear to be primarily associated with patient characteristics rather than the use of additional add-on interventions. These findings support the implementation of a cautious and evidence-based approach to add-on use in clinical practice. Trial registration number No

Zitieren

APA

Moriyama, A., Kuroda, K., Tsutsumi, R., Ohgi, S., Hobo, R., Nakagawa, R., Nakata, M., Motoyama, H., Kuribayashi, Y., & Sugiyama, R. (2026). L26/P-495 Pregnancy outcomes following add-on interventions in women aged. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.828

Vancouver

Moriyama A, Kuroda K, Tsutsumi R, Ohgi S, Hobo R, Nakagawa R, et al. L26/P-495 Pregnancy outcomes following add-on interventions in women aged. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.828

BibTeX
@article{Moriyama2026,
  author = {Moriyama, A. and Kuroda, K. and Tsutsumi, R. and Ohgi, S. and Hobo, R. and Nakagawa, R. and Nakata, M. and Motoyama, H. and Kuribayashi, Y. and Sugiyama, R.},
  title = {L26/P-495 Pregnancy outcomes following add-on interventions in women aged},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.828}
}
Kostenlos starten →